We observed changes in the distribution of exchangeable apolipoproteins following addition of recombinant apolipoproteins or interaction with exogenous compounds.
Introduction
Lipoprotein particles are complex structures and the subject of several studies where different functions have been attributed to both lipid (1) and associated protein (2) (3) (4) (5) (6) components. Apolipoproteins are of particular importance as demonstrated for apolipoprotein (apo)B, the major apolipoprotein of LDL (7) . The proteins in HDL constitute more than half of its mass and include those with well characterized functions (ApoA-I, ApoA-II, ApoE, ApoC's), enzymes (LCAT, paraoxonase 1), and also numerous but less abundant apolipoproteins with poorly characterized functions (8, 9) . In addition, most are considered exchangeable apolipoproteins that can distribute to lipoproteins of different densities and might have different functions or might indicate different health status. For example, apoE is mainly associated with large HDL particles in the general population, but is also associated with VLDL and LDL particles in hyperlipidemia and dyslipidemia (10) .
Other examples whereby protein function may be influenced by its association with a particular lipoprotein include phospholipid transfer protein (PLTP), which has been reported to be active when associated with HDL, but inactive when associated with LDL or VLDL (11) . In contrast, Lp-PLA 2 is active when associated with LDL but less active in HDL (12) and considered a biomarker for cardiovascular disease risk assessment. The implications of these differences on a beneficial versus detrimental role of these proteins are poorly understood, partly due to lack of suitable techniques to study their associations in large sample sets.
Since the highly complex protein composition of plasma poses a challenge to analysis (13) , separation into lipoprotein subpopulations may initially reduce this complexity. Notably, the separation of plasma lipoprotein particles by by guest, on October 14, 2017 www.jlr.org Downloaded from ultracentrifugation or isotachophoresis may change lipoprotein composition by detaching loosely bound proteins (5, 14) . Gel electrophoresis, and 2D gels in particular, has a non-paralleled separation power but gel preparation (15, 16) , protein extraction and characterization are laborious. Protein association is well preserved by using size exclusion chromatography (SEC); a method that also allows reasonably high throughput and is applicable to large clinical studies. The similarity of separation by SEC to ultracentrifugation has been shown and rigorous assessments of SEC have been made (17, 18) .
Reverse phase arrays (RPA) are ideally suited for rapid analysis of tens of analytes from small volumes of fractionated plasma. Analyte-containing samples are immobilized on a solid support and assessed using appropriate antibodies, i.e., in contrast to forward phase arrays where the antibody is immobilized. Use of RPA is well established for characterization of proteins in cell and tissue lysates (19) .
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Materials and Methods
Blood donors and size exclusion chromatography
Human plasma samples were provided by healthy volunteers from a clinical study conducted in accordance with the Declaration of Helsinki and approved by independent ethics committees. All participants provided written informed consent. A general schematic of the technique described is provided in Fig. 1 . In brief, EDTA plasma samples were centrifuged for 4 min at 1200 rpm (113x g) and 100 µl of supernatant diluted with 100 µl of SEC solution (0.15 M NaCl, 1 mM EDTA, pH 8.0) prior to being loaded onto the separation system. SEC was carried out using an ÄKTApurifier 10 (GE Healthcare, Uppsala, Sweden) consisting of a compact separation unit, equipped with an autosampler A900, a fraction collector Frac-950 and a Superose 6 column (10/300GL, 10 x 300-310 mm, 24 ml). The system was controlled by a UNICORN control system version 4.10 (GE Healthcare, Uppsala, 6 Total cholesterol concentration was determined in each fraction as previously described (7) using a microenzymatic fluorescence assay employing cholesterol esterase, cholesterol oxidase, and peroxidase together with the fluorogenic substrate p-hydroxyphenylacetic acid (p-HCA).
Preparation of reverse phase arrays
Fractions from SEC separation were thawed and 50 µl of each fraction was transferred to a 384-well plate, the "spotting plate" (Eppendorf low protein bind 200 µl) using an automated pipetting robot (Sephyr and Twister, Caliper Life Sciences, Hopkinton, MA). Fractions were spotted in 0.4 nl aliquots onto nitrocellulose membrane coated microscope slides (Whatman/GE Healthcare FastSlides or Schott Nexterion white nitrocellulose slides) in a predefined pattern using a contact-free inkjet dispenser with a piezo-actuated nozzle (Nanoplotter 2.1E, GeSiM, Grosserkmannsdorf, Germany). Four concentrations of each fraction were generated by applying up to four drops on one location, referred to as "spot". Arrays held a maximum of 4608 spots, equivalent to 48 fractions from 24 samples spotted at four concentrations. Up to 60 replicate slide copies were produced from each fraction set.
Each slide copy was incubated with a different primary antibody raised against a particular protein and a corresponding fluorescently labeled secondary antibody. To reduce the influence of slide variation, all fractions from one individual (e.g., at different time points or doses) were combined on one slide. Data relating to each slide and associated fraction set were identified using a barcode system and collated. 7 blocking, dilution of antibodies and washing. ApoA-I was detected using an in-house mouse monoclonal antibody (MAB) directly conjugated to Alexa647. All other antibodies and detection reagents were from commercial sources and used as recommended by the supplier. Reagent suppliers, dilution factors, final antibody concentrations, and incubation times of primary and secondary antibodies can be found in Table 1 and Table 2 . (1 µM). All compounds studied were synthesized using standard procedures. rhCETP was expressed by a cell line described by Weinberg et al (8) , kindly provided by Professor Alan Tall (Columbia University) and purified by hydrophobic interaction chromatography and SEC (modified from Ohnishi et al. [22] ).
ELISA for the detection of CETP
NUNC maxisorp plates were coated with anti-CETP capture antibody clone 6/2 (5 µg /ml) in a total volume of 100 µl/well using washing buffer (PBS, 0.05% Tween-20)
overnight at 4°C in a humid box. After washing with washing buffer, wells were blocked with blocking buffer (assay buffer [50 mM Tris, 140 mM NaCl, 5 mM EDTA, 0.05% NONidet P40, 0.25% gelatine -all adjusted to pH 7.4] plus 1 % BSA) for 1 h at 37°C. 50 µl of each fraction was applied to each well and incubated for 1 h at 37°C.
Wells were rinsed and incubated with 50 µl HRP-conjugated antibody clone 6/17 (0.5 µg/ml) for 1 h at room temperature. After thorough rinsing of wells, the plates were incubated for 5 min at room temperature with 100 µl/well of substrate mix containing by guest, on October 14, 2017
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Results
Distribution of proteins is consistent with previous findings
The spotting process, using SEC-derived fractions, allowed several dozen identical slides to be produced automatically. This approach towards the analysis of spotted samples with antibodies is similar to a dot blot. However, the RPA approach is dramatically miniaturized. Using the classical macroscopic dot blot technique, typically the entire fraction of 500 µl is used to prepare one blot only; here less than 20 µl of each fraction is used while producing up to 60 identical "blot copies" in one spotting run. Each copy can then be incubated with a different antibody ( With this technology, as expected, the major ApoA-I peak coincided with the HDL-cholesterol (HDL-C) peak in samples from untreated healthy volunteers, with no detection of ApoA-I in other particle populations. The ApoB peak coincided with the cholesterol peaks representing VLDL and LDL, also as expected (9) . ApoE was detected in particles larger than in those comprising the major HDL-C peak but smaller than particles comprising the major LDL-C peak (Fig. 1B-G ) consistent with previous findings (10) . This illustrated the ability of this technology to identify and describe lipoprotein particles by means other than their cholesterol content alone.
The active form of PLTP, detected with a PAB, was associated to HDL whereas the inactive form, detected in addition to the active form by a MAB, was also associated to VLDL and LDL as per previous observations (11) . The technology is therefore also capable of distinguishing different forms or conformations of a given protein.
Sensitivity and surface saturation effect
Inherent to separation by SEC, analytes will in general be more diluted in the fractions than in total plasma, which could compromise sensitivity towards low abundant analytes. To overcome this, during spotting we deposited multiple drops of each fraction onto nitrocellulose membrane coated slides, thus increasing the concentration of analytes per unit area. However, full saturation of the surface area available had to be avoided to maintain measurements within the linear range. The deposition of 1, 2, 3, and 4 drops of each fraction each at a given spot facilitated the concentration of low level analytes and the assessment of linearity during the analysis. The linearity was inspected by plots of relative fluorescence intensity for the four concentrations ( Fig. 2A) . If saturation was approached, the four concentrations would display high RFI values, but a slope approaching zero. Hence, mean RFI versus the slope of four concentrations of each fraction were routinely plotted as a means of quickly controlling linear surface coverage in all experiments (Fig. 2B) . In this way, the entire process was optimized to completely avoid surface saturation; in particular, the amount of plasma loaded on the column (ideal: 200 µl, 1:1 diluted EDTA-plasma). Further dilution of fractions prior to spotting was explored also but undiluted fractions proved more effective. We also tested different microarray surface coatings; slides coated with a nitrocellulose membrane yielded a dynamic range of more than three orders of magnitude in protein concentration and a much better were determined for those analytes where purified proteins were available by spotting dilution series of the respective proteins. LLOD's were 310 ng/ml for ApoA-I and 6 ng/ml for CETP; levels significantly below published concentrations in full plasma.
Assessment of antibody specificity
For each analyte, we tested several different commercially available or in-house produced antibodies on sets of SEC fractions representing different conditions. Each antibody was tested at different concentrations and with different incubation times.
The position of analyte peaks from the resulting profiles were compared with published reports of associations of analyte to lipoprotein particle subfractions (e.g., In addition to thorough evaluation of primary antibodies, it was crucial to assess the cross-reactivity of detection reagents. Streptavidin binding to fractions was negligible and biotinylated primary antibodies were therefore preferred. As such conjugates are not always available and biotinylation can change the specificity of primary antibodies, we carefully evaluated cross-reactivity of secondary antibodies to the fractions. Optimal results were obtained with commercially available secondary antibodies, which were cross-absorbed against IgG's from several different species (so-called highly cross absorbed).
Association of CETP to lipoproteins is increased by a CETP inhibitor
The proper activity and function of recombinant human (rh)CETP was confirmed by a cholesterol transfer assay and decrease of HDL-C with increase of LDL-C in cholesterol profiles (data not shown). (Fig. 3A, fractions 36-40) . Added rhCETP increased only the peak in relatively late fractions, also found during purification of rhCETP; the protein from these late fractions remained functional. Unexpectedly long retention times for CETP have been reported previously, albeit referred to as lipid transfer protein at that time (13) .
In the presence of the CETP inhibitor torcetrapib, CETP was not detected in late fractions, but co-eluted with LDL and HDL, indicating a stronger association to lipoproteins when inhibitor is present; a finding confirmed by ELISA employing different antibodies for the capture and detection of CETP. The redistribution of CETP upon inhibition has been described previously (14) providing further validation of the technology.
CETP-induced formation of pre-β-HDL particles
Most striking was the observed formation of an additional ApoA-I peak with increasing concentrations of rhCETP, which appeared in fraction 29, i.e., following the principal HDL-C peak (fractions 23 to 27). All of the fractions shown in Fig. 4 were also analyzed for other apolipoproteins. Of those lipoproteins detected in fraction 29, only ApoA-I levels were changed by rhCETP (Fig. 5) . These small particles, which contained almost exclusively ApoA-I were identified using agarose gel electrophoresis followed by western blotting (15) as pre-β-HDL particles, a nascent form of HDL with a low cholesterol content and involved in reverse cholesterol transport (RCT). The activity of CETP towards increasing ApoA-I in pre-β-HDL particles has been previously described (28). When 1 µM of either CETP inhibitor torcetrapib or anacetrapib was co-incubated with plasma and increasing concentrations of rhCETP, CETP-induced formation of pre-β particles was completely abolished (Fig. 4C and D) . In contrast, in the presence of 3 µM of the CETP modulator dalcetrapib, CETP-dependent formation of pre-β particles was conserved ( Fig. 4B and E) . 
